|Secondary Protocol No.
||MT2004-24 Autologous Peripheral Blood Stem Cell Transplant for Patients with Lymphoma
||This trial is studying how well autologous peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
||The study involves patient's blood stem cell collection, chemotherapy before and after transplant, with or without radiation, and stem cell transplant. After completion of study treatment, patients are followed periodically.
||Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored for peripheral stem cell transplant. Giving more chemotherapy, such as cyclophosphamide, carmustine, and etoposide, and total-body irradiation prepares the patient's bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. More radiation therapy is given after transplant to kill any remaining cancer cells.
||Patients diagnosed with Hodgkin's Lymphoma and Non Hodgkin's Lymphoma are eligible. Patients with HIV infection are eligible.
|Applicable Disease Sites
||Blood and Marrow Transplant
Total Body Irradiation (TBI)
||BCNU (CARMUSTINE, BICNU)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
||Masonic Cancer Center
||Patient must be no more than 75 years of age. Adequate organ function is required. Women who are pregnant or nursing are not eligible. Patients who are eligible for any higher priority transplant protocols and patients with chemotherapy resistant disease are not eligible. A signed informed consent and HIPAA authorization are required; assent form is also required if patient is a minor.